Good stuff, Coocoobura. I'd narrow down the competitive threats to baricitinib and tocilizumab, not so much because of their superior effectiveness but because they are FDA-approved (for other indications), BP chemicals and will be able to move through the regulatory process much better than CYDY, which has been having a lot of trouble getting the job done.

AND the feds do much of the work for them...with BARDA and with actually funding and conducting massive trials for them (like with remdesivir)...aarrgh!